Cellular Biomedicine Group Stock Forecast for 2022 - 2025 - 2030
Updated on 05/25/2022
Cellular Biomedicine Group Fair Value Forecast for 2022 - 2025 - 2030
Cellular Biomedicine Group's Fair Value has increased by 100% in the last one years, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach an impressive $0.00 – an increase of 100%. For the next eleven years, the forecast is for Fair Value to grow by 100%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|
Cellular Biomedicine Group Revenue Forecast for 2022 - 2025 - 2030
Cellular Biomedicine Group's Revenue has increased by 54.55% in the last one years, going from $220.00k to $340.00k. In the next year, analysts expect Revenue to reach a reasonable $459.99k – an increase of 35.29%. For the next eleven years, the forecast is for Revenue to grow by 710.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|
Cellular Biomedicine Group Free Cash Flow Forecast for 2022 - 2025 - 2030
In the past one years, Cellular Biomedicine Group's Free Cash Flow has seen a tremendous increase, going from $-31700000.00 to $-50320000.00 – an increase of 58.74%. In the following year, the 0 analysts surveyed believe that CBMG's Free Cash Flow will decrease by 37%, reaching a dismal $-41047931.05. According to professionals, by 2030, Cellular Biomedicine Group's Free Cash Flow will have decreased by 18.43%, falling all the way down to $-41047931.05.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|
Cellular Biomedicine Group Net Income Forecast for 2022 - 2025 - 2030
In the last one years, Cellular Biomedicine Group's Net Income has grown by 28.32%, from $-38950000.00 to $-49980000.00. For the following year, the 0 analysts predict that CBMG's Net Income will drop by 22.07%, reaching $-43547246.64. In 2030, the professionals' prediction is that CBMG's Net Income will decrease by 12.87%, reaching $-43547246.64.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|
Cellular Biomedicine Group EBITDA Forecast for 2022 - 2025 - 2030
In the last one years, Cellular Biomedicine Group's EBITDA has grown by 39.37%, rising from $-32540000.00 to $-45350000.00. The next year, 0 experts forecast that Cellular Biomedicine Group's EBITDA will decrease by 28.25%, reaching $-38286326.07. In 2030, professionals predict that Cellular Biomedicine Group's EBITDA will decrease by 15.58%, reaching $-38286326.07.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|
Cellular Biomedicine Group EBIT Forecast for 2022 - 2025 - 2030
In the last one years, Cellular Biomedicine Group's EBIT has grown by 35.65%, rising from $-37590000.00 to $-50990000.00. According to the 0 analysts polled, in the next year, CBMG's EBIT will fall by 26.28%, reaching a lowly $-43462851.82. By 2030, professionals believe that Cellular Biomedicine Group's EBIT will have decreased by an astonishing 14.76%, plummeting to just $-43462851.82.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|
Cellular Biomedicine Group EPS Price Prediction Forecast for 2022 - 2025 - 2030
Cellular Biomedicine Group's EPS has increased by 49.43% in the last one years, going from $-1.76 to $-2.63. In the following year, 0 experts forecast that Cellular Biomedicine Group's EPS will decrease by 33.08%, to $-2.17. In 2030, professionals predict that Cellular Biomedicine Group's EPS will decrease by 17.31%, to $-2.17.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|